HOME >> MEDICINE >> NEWS
Are one-third of costly implanted heart devices unnecessary? New study suggests yes

ANN ARBOR, Mich. -- This year, Medicare will pay for tens of thousands of heart patients to have high-tech devices implanted in their chests. Called ICDs or implantable cardioverter defibrillators, the expensive devices are designed to shock damaged hearts back into rhythm and save patients from sudden cardiac death, which kills 300,000 Americans each year.

But a new study finds that while many of these patients will benefit from their ICDs, a large number won't -- and a simple heart-rhythm test can tell who's who.

In fact, the study suggests that if the test were used on the majority of ICD candidates, as many as one-third could be spared the operation to implant a device, without raising their risk of sudden death. That would mean that Medicare could be spared the additional $90,000 lifetime cost of each device compared to best medical therapy.

The study, published in the January issue of the Journal of the American College of Cardiology, is based on data from 768 patients who were candidates for ICDs at Christ Hospital and the Ohio Heart and Vascular Center in Cincinnati. All of the patients had survived heart attacks but had permanent damage to their heart muscle caused by lack of blood flow -- a condition called ischemic cardiomyopathy.

Each patient received a test called microvolt T-wave alternans or MTWA, along with a battery of other tests, during their evaluation. Half of the patients went on to receive ICDs, although the MTWA test results weren't used in the decision-making process. The patients' health and the causes of any deaths were tracked for up to three years.

After that time, the data were analyzed by researchers from the University of Michigan Cardiovascular Center and VA Ann Arbor Healthcare System, in cooperation with the Ohio team.

In all, 67 percent of patients had positive or inconclusive MTWA test results. Of them, the patients who went on to receive an ICD were 55 percent less
'"/>

Contact: Kara Gavin
kegavin@umich.edu
734-764-2220
University of Michigan Health System
3-Jan-2007


Page: 1 2 3

Related medicine news :

1. New study: Preterm birth causes one-third of all infant deaths
2. More than one-third of disaster victims may suffer from stress disorder
3. HIV infection rates down one-third in south India, University of Toronto study
4. Traditional risk-factor scoring misses one-third of women vulnerable to coronary heart disease
5. Only one-third of women take vitamin to help prevent serious birth defects, survey finds
6. Resident work hour restrictions may be costly for teaching hospitals
7. ADHD costly before and after diagnosis
8. Oops! Researchers publish new findings on the brains response to costly mistakes
9. Headlines about Herceptin show equality of access to costly drugs must be tackled
10. Bipolar disorder more prevalent and costly than believed; Lithium could curb suicide rate
11. Prescription of heroin is less costly for society

Post Your Comments:
(Date:4/27/2015)... (PRWEB) April 27, 2015 Covenant Care, ... nationwide, has rolled out its “Enhanced Dining” service with ... foods developed with input from residents, patients and families ... and the redesign of its dining rooms so that ... the quality of life for our residents is our ...
(Date:4/26/2015)... (PRWEB) April 26, 2015 The ... both inpatient and outpatient therapy facilities that provide physical, ... years to 2015, the industry has experienced revenue growth ... acceptance of the benefits of physical therapy services. The ... helped support industry revenue growth during the period because ...
(Date:4/26/2015)... Indiana Fiber Network, LLC (IFN), the leading Indiana ... Company has selected IFN as a fiber transport provider. ... Mutual Insurance Company states: “IFN’s broadband fiber solution created ... We were interested in building entrance and ... ensure we achieved both. ” , According ...
(Date:4/26/2015)... India Network Foundation, a non-profit organization in ... to the Asian Indian community in the United States ... than two decades. The India News Network Digest of ... the world with the latest news items from India, ... Law Forum Digest, edited and contributed by Sheela Murthy, ...
(Date:4/26/2015)... The grand celebration got off to a festive start with ... Deb then introduced Sandy Valentine, the wife of CCAR’s Executive ... his Walk for Recovery on the Appalachian Trail. ... gratitude to the volunteers via video. Board President Tom Kirk ... CCAR’s mission. Volunteer Manager Conrad Sienkiewicz read the names ...
Breaking Medicine News(10 mins):Health News:Covenant Care Rolls Out "Enhanced Dining" Offering Restaurant Style Experience To Residents, Patients & Families 2Health News:Physical Therapy Rehabilitation Centers in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Physical Therapy Rehabilitation Centers in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 2Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 3Health News:The Connecticut Community for Addiction Recovery (CCAR) honors its volunteers during National Volunteer Recognition Week. 2
(Date:4/24/2015)... -- Hospira, Inc. (NYSE: HSP ), ... spoke about the importance of extrapolation in bringing biosimilars ... annual European Biosimilars Group conference in London ... publication of a pivotal white paper titled, "Why ... biosimilars." Speaking at the EGA conference, ...
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ABBV ... Administration (FDA) has accepted its New Drug Application (NDA) ... two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), ... of adults with chronic genotype 4 (GT4) hepatitis C ... first all-oral, interferon-free therapy being evaluated by the FDA ...
(Date:4/23/2015)... 23, 2015 Once again, BeaconMedaes is meeting ... to patient safety. BeaconMedaes, priority is to ... disease. The next generation Zone Valve Box ... are now mounted in the assembly, allowing for ease ... ceiling tiles potentially releasing dust spores and other bacteria ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2
Cached News: